Surfactant protein D and KL-6 serum levels in systemic sclerosis: Correlation with lung and systemic involvement

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 28, Issue 1, 2011, Pages 27-33

  Bonella, F ^a,c   Volpe, A ^a   Caramaschi, P ^a   Nava, C ^a   Ferrari, P ^a   Schenk, K ^a   Ohshimo, S ^b   Costabel, Ulrich ^c   Ferrari, M ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b HIROSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Anti Scl 70; KL 6; Lung fibrosis; SP D; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; PREDNISONE; PROTEIN; PROTEIN KL 6; SCL 70 ANTIBODY; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL DISEASE; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; LUNG INTERSTITIUM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 79960470401     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009; 48: 40-4.
3. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-6. (Pubitemid 20168722)
4. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994; 37: 391-4. (Pubitemid 24093631)
5. Day AJ. The C-type carbohydrate recognition domain (CRD) superfamily. Biochem Soc Trans 1994; 22: 83-8. (Pubitemid 24072393)
6. Kohno N, Akiyama M, Kyoizumi S, et al. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18: 203-16.
7. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
8. Yanaba K, Hasegawa M, Hamaguchi Y, Fujimoto M, Takehara K, Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003; 21: 429-36. (Pubitemid 36950310)
9. Hant FN, Ludwicka-Bradley A, Wang HJ, Li N, Elashoff R, Tashkin DP, Silver RM; Scleroderma Lung Study Research Group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009; 36: 773-80.
10. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
11. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6. (Pubitemid 32660630)
12. Clements P, Lachenbrach P, Siebold J, et al. Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
13. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2002; 21: S5-8.
14. Valentini G, Delia Rossa A, Bombardiert S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
15. Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest 1999; 116: 715-20.
16. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-20. (Pubitemid 38715886)
17. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-83. (Pubitemid 27406888)
18. Quanjer, PH, Tammeling GJ, Cotes JE. Standardized lung function testing. Eur Respir J 1993; 6: S1-52.
19. Asano Y, Ihn H, Yamane K, et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001; 44: 1363-9. (Pubitemid 32537535)
20. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000; 162: 1109-14.
21. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. (Pubitemid 18073738)
22. Medsger TA, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis. Development and testing. J Rheumatol 1999; 26: 2159-62.
23. Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma, where histological and clinical scores meet. Rheumatology 2007; 46: 833-41. (Pubitemid 47061718)
24. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006; 73: 490-4.
25. Reveille JD, Solomon DH; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399-412.
26. Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983; 42: 23-37.
27. Steen VD, Powell DL, Medsger TA. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196-203. (Pubitemid 18088039)
28. Parodi A, Puiatti P, Rebora A. Serological profile as prognostic clues for progressive systemic scleroderma: the Italian experience. Dermatologica 1991; 183: 15-20.
29. Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 1: 75-83. (Pubitemid 24027696)
30. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun 2005; 30; 338: 1845-52. (Pubitemid 41643100)
31. Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med 2004; 53: 74-7. (Pubitemid 38899739)
32. Liu S, Taghavi R, Leask A. Connective tissue growth factor is induced in bleomycin-induced skin scleroderma. J Cell Commun Signal 2010; 4: 25-30